PDCD1 and hepatocellular carcinoma: A non-comparative phase I/II CheckMate 040 trial of Nivolumab (NCT01658878) with 262 patients with advanced HCC showed the safety and efficacy of PD-1 inhibitor in treating HCCs (26).